Ablative immunotherapy

Details Ablative immunotherapy Ablative immunotherapy

2011-07-05

2011-07-05

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C424S093100

Reexamination Certificate

active

07972594

ABSTRACT:
The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.

REFERENCES:
patent: 5837251 (1998-11-01), Srivastava
patent: 6136315 (2000-10-01), Srivastava
patent: 6139841 (2000-10-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6277368 (2001-08-01), Hiserodt et al.
patent: 6797480 (2004-09-01), Srivastava
patent: 6875849 (2005-04-01), Graner et al.
patent: 2004/0228848 (2004-11-01), Har-Noy
patent: 2005/0191291 (2005-09-01), Har-Noy
Eibl et al., 1996, Blood vol. 88, pp. 1801-1808.
Bishop et al., 2004,J Clin Oncol. 22, pp. 3886-3892.
Sabel et al (Breast Cancer Research and Treatment, 2005, 90:97-104).
Bishop et al (J Clinical Oncology, 2004, 22:3886-3892).
Eibl et al (Blood, 1996, 88:1501-1508).
Machlenkin et al., Clinical Cancer Research Jul. 1, 2005 11, 49561.
Mecher et al., Cancer Research vol. 59, pp. 2802-2805, 1999.
Ablin, R. J., et al. (1982). “Cryoimmunotherapy: a conference report.”Eur Surg Res14(4) : 309-16.
Banchereau, J., F. Briere, et al. (2000). “Immunobiology of dendritic cells.”Annu Rev Immunol18: 767-811.
Banchereau, J. and R. M. Steinman (1998). “Dendritic cells and the control of immunity.”Nature392(6673): 245-52.
Bell, D., J. W. Young, et al. (1999). “Dendritic cells.”Adv Immunol72: 255-324.
Berzofsky, J. A., J. D. Ahlers, et al. (2004). “Progress on new vaccine strategies against chronic viral infections.”J Clin Invest114 (4): 450-62.
Berzofsky, J. A., M. Terabe, et al. (2004) . “Progress on new vaccine strategies for the immunotherapy and prevention of cancer.”J Clin Invest113 (11) : 1515-25.
Boon, T., J. C. Cerottini, et al. (1994). “Tumor antigens recognized by T lymphocytes.”Annu Rev Immunol12: 337-65.
Fujii, S., K. Liu, et al. (2004). “The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.”J Exp Med199(12): 1607-18.
Gallucci, S., M. Lolkema, et al. (1999). “Natural adjuvants: endogenous activators of dendritic cells.”Nat Med5(11): 1249-55.
Gazzaniga, S., A. Bravo, et al. (2001). “Inflammatory changes after cryosurgery-induced necrosis in human melanoma xenografted in nude mice.”J Invest Dermatol116(5) : 664-71.
Knutson, K. L. and M. L. Disis (2004). “IL-12 enchances the generation of tumour antigen-specific Thl CD4 T cells during ex vivo expansion.”Clin Exp Immunol135(2) : 322-9.
Matzinger, P. (2002). “The danger model: a renewed sense of self.”Science296(5566): 301-5.
Matzinger, P. (2002). “An innate sense of danger.”Ann N Y Acad Sci961: 341-2.
Mazur, P. (1984). “Freezing of living cells: mechanisms and implications.”Am J Physiol247(3 Pt 1): C125-42.
Orpwood, R. D. (1981). “Biophysical and engineering aspects of cryosurgery.”Phys Med Biol26(4): 555-75.
Ostrowski, M. A., Q. Yu, et al. (2006). “Why can't the immune system control HIV-1? Defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity.”Immunol Res35(1-2): 89-102.
O'Sullivan, B. and R. Thomas (2003). “CD40 and dendritic cell function.”Crit Rev Immunol23(1-2): 83-107.
Pardoll, D. M. (2002). “Spinning molecular immunology into successful immunotherapy.”Nat Rev Immunol2(4): 227-38.
Reis e Sousa, C. (2001). “Dendritic cells as sensors of infection.”Immunity14(5): 495-8.
Rosenberg, S. A. (2004). “Development of effective immunotherapy for the treatment of patients with cancer.”J Am Coll Surg198(5): 685-96.
Sauter, B., M. L. Albert, et al. (2000). “Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.”J Exp Med191(3): 423-34.
Segal, B. H., X. Y. Wang, et al. (2006). “Heat shock proteins as vaccine adjuvants in infections and cancer.”Drug Discov Today11(11-12): 534-40.
Shi, Y., W. Zheng, et al. (2000). “Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.”Proc Natl Acad Sci U S A97(26): 14590-5.
Thimme, R., V. Lohmann, et al. (2006). “A target on the move: innate and adaptive immune escape strategies of hepatitis C virus.”Antiviral Res69(3): 129-41.
Waldmann, T. A. (2003). “Immunotherapy: past, present and future.”Nat Med9 (3): 269-77.
Rubinsky, B., et al. (2007). “Irreversible Electroporation: A New Ablation Modality—Clinical Implications.”Technology in Cancer Research and Treatmentvol. 6, No. 1: 1-12.
Encke, J. et al., “Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection”, Clinical and Experimental Immunology, 2005, vol. 142, pp. 362-269.
Agrewala, J.N. et al., “Delivery of antigen in allogeneic cells preferentially generates CD4+Th1 cells”, Clinical and Experimental immunology, 2003, vol. 134, pp 13-22.
Gong, J. et al., “Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induced antitumor immunity”, The Journal of Immunology, 2000, vol. 165, pp. 1705-1711.
Devarapu S.K. et al., “Triggering of T cell-meidated immune responses by allogenic tumor cell vaccine in patients with oral cancer”, Immunopharmacology and Immunotoxicology, Sep. 2006, vol. 28, pp. 387-395.
PCT International Search Report, Feb. 25, 2009.

Affiliated with

Also associated with

Rating

Ablative immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ablative immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ablative immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2740393